Recently, the 23rd CPHI China—China International Pharmaceutical Ingredients Exhibition—was grandly held at the Shanghai New International Expo Center, bringing together the global pharmaceutical industry’s leading players and forging deep connections with international markets and premium resources. Beijing Minhai Biotechnology Co., Ltd., along with its parent company Kintor Pharmaceutical, once again showcased its groundbreaking products at this prestigious event, including the world’s first “dual‑carrier” 13‑valent pneumococcal polysaccharide conjugate vaccine and the globally exclusive 60‑microgram hepatitis B vaccine, while engaging with partners to discuss cutting-edge industry trends and explore potential collaboration opportunities.
During the exhibition, Kangtai Minhai showcased its diversified product portfolio, robust R&D strategy, and stringent quality management system, earning widespread attention and recognition from attendees through a proactive and open approach to collaboration. The company engaged in in-depth discussions with numerous corporate clients from Southeast Asia, South Asia, the Middle East, Africa, the Commonwealth of Independent States, Latin America, and other regions. These markets exhibit significant public health potential, with local health authorities and consumers alike expressing strong demand for high‑quality, cutting‑edge vaccine products. At the event, several partners reached preliminary agreements on potential collaborations.
The International Business Team of Kangtai Group stated: “The annual CPHI exhibition serves as a vital bridge for pharmaceutical companies worldwide to exchange ideas, and it also provides an excellent platform for us to showcase our comprehensive strength and internationalization strategy. Moving forward, Kangtai Biologics is committed to working with more partners, leveraging diverse approaches such as finished‑product exports, technology transfer, and localized production, to advance equitable global vaccine distribution and safeguard the health of more people.”
